Tan­go Ther­a­peu­tics nabs $60M in CRISPR-based hunt for hid­den can­cer genes

Like a few oth­er CEOs, Bar­bara We­ber emerged from the JP Mor­gan Health­care Con­fer­ence up­beat. She had been test­ing the wa­ters of a Se­ries B for her can­cer start­up, Tan­go Ther­a­peu­tics, since the fall and af­ter a few in­vestor meet­ings in San Fran­cis­co, a lead in­vestor had stepped for­ward, set­ting the stage for a size­able round.

“We just didn’t re­al­ize that in the mid­dle of that we’d end up in a glob­al pan­dem­ic,” We­ber told End­points News. “I won’t lie to you, it was a lit­tle nerve-wrack­ing — when we were just get­ting things sort­ed out and do­ing al­lo­ca­tions, the first mar­ket crash hap­pened.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER